IP Library Granted Patent US 8,012,947
Granted Patent B2
US 8,012,947 · App. 12/047,106 · Granted Sep 6, 2011

Methods and compositions for promoting wound healing

Assignee: Hospital for Special Surgery
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,012,947
App. No.
12/047,106
Granted
Sep 6, 2011
Kind
B2
Abstract

Provided herein are compositions and methods that inhibit expression of Adam12 gene products, such as ADAM12 mRNA and/or ADAM12 polypeptides, as a therapeutic approach for the treatment of, or promotion of healing of, wounds.

Claims (17)

1. A method of promoting healing of a chronic wound, comprising:

administering to the wound an amount of a selective ADAM12 inhibitory compound effective to promote healing of the wound,

in which the ADAM12 inhibitory compound inhibits expression of mRNA encoding ADAM12.

2. The method of claim 1 in which the ADAM12 inhibitory compound is an antisense oligonucleotide, an iRNA, an siRNA, or a nucleic acid encoding an antisense oligonucleotide, an iRNA or an siRNA.

3. The method of claim 1 or claim 2 in which the ADAM12 inhibitory compound is administered locally to the wound.

4. The method of claim 3 in which the ADAM12 inhibitory compound is included in a dressing that is applied topically to the wound.

5. The method of claim 3 in which the ADAM12 inhibitory compound is administered locally to the wound via injection.

6. The method of claim 2 in which the ADAM12 inhibitor compound is an antisense oligonucleotide.

7. The method of claim 2 in which the ADAM12 inhibitor compound is a siRNA.

8. A method of promoting healing of a chronic wound, comprising:

administering to the wound an amount of a selective ADAM12 inhibitory compound effective to promote healing of the wound,

in which the ADAM12 inhibitor compound is an antibody.

9. The method of claim 8 , wherein the antibody is administered locally to the wound.

10. The method of claim 9 , wherein the antibody is administered locally to the wound via injection.

11. The method of claim 8 , wherein the antibody is administered topically to the wound.

12. The method of claim 11 in which the antibody is included in a dressing that is applied topically to the wound.

13. The method of claim 1 or claim 8 , wherein the chronic wound is an arterial ulcer, a diabetic foot ulcer or a venous ulcer.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 9, 2022
From: HOSPITAL FOR SPECIAL SURGERY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061902/0132 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2008
From: TOMIC, MARJANA; BLOBEL, CARL PETER; HARSHA, ASHEESH
To: HOSPITAL FOR SPECIAL SURGERY
Reel/Frame 021806/0926 →
Continuity (2)
Provisional Application 60918367 · Mar 15, 2007
Related Publication 20090068251A1 · Mar 12, 2009